, /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company is set to join the Russell Microcap Index at the conclusion of the 2024 Russell U.S.
Indexes annual reconstitution, effective at the open of U.S. equity markets on , according to preliminary lists of additions posted on .
The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.
S. stocks as of , ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "Our inclusion in the Russell index is representative of the growth that the Company has undergone since becoming a publicly traded company in the first quarter of 2023," said , Ph.D.
, Chief Executive Officer of CalciMedica. "I am grateful to all our employees at CalciMedica for their diligent work in pursuit of our goal of delivering much-needed therapies to patients suffering from acute and chronic inflammatory and immunologic illnesses, while continuing to create value for our stockholders." Russell indexes are widely us.
